While UV radiation can assist in the production of vitamin D, excessive exposure to UV can damage health. Evolution of skin color
Loss of body hair in Hominini species is assumed to be related to the emergence of bipedalism some 5 to 7 million years ago. Bipedal hominin body hair may have disappeared gradually to allow better heat dissipation through sweating. The emergence of skin pigmentation dates to about 1.2 million years ago, under conditions of a  megadrought that drove early humans into arid, open landscapes. Such conditions likely caused excess UV-B radiation. This favored the emergence of skin pigmentation in order to protect from folate depletion due to the increased exposure to sunlight. A theory that the pigmentation helped counter xeric stress by increasing the epidermal permeability barrier has been disproved.With the evolution of hairless skin, abundant sweat glands, and skin rich in melanin, early humans could walk, run, and forage for food for long periods of time under the hot sun without brain damage due to overheating, giving them an evolutionary advantage over other species. By 1.2 million years ago, around the time of Homo ergaster, archaic humans (including the ancestors of Homo sapiens) had exactly the same receptor protein as modern sub-Saharan Africans.This was the genotype inherited by anatomically modern humans, but retained only by part of the extant populations, thus forming an aspect of human genetic variation.
Meclofenamic acid (used as meclofenamate sodium, brand name Meclomen) is a drug used for joint, muscular pain, arthritis and dysmenorrhea. It is a member of the anthranilic acid derivatives (or fenamate) class of nonsteroidal anti-inflammatory drugs (NSAIDs) and was approved by the US FDA in 1980. Like other members of the class, it is a cyclooxygenase (COX) inhibitor, preventing the formation of prostaglandins.Scientists led by Claude Winder from Parke-Davis invented meclofenamate sodium in 1964, along with fellow members of the class,  mefenamic acid in 1961 and flufenamic acid in 1963.: 718 Patents on the drug expired in 1985: 295  and several generics were introduced in the US, but as of July 2015 only Mylan still sold it.It is not widely used in humans as it has a high rate (30-60%) rate of gastrointestinal side effects. : 310

Adverse effects
In October 2020, the U.S. Food and Drug Administration (FDA) required the drug label to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid. They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy. Use in horses
Meclofenamic acid is sold under the trade name "Arquel" for use in horses, and is administered as an oral granule form at a dose of 2.2 mg/kg/day. It has a relatively slow onset of action, taking 36–48 hours for full effect, and is most useful for treatment of chronic musculoskeletal disease.